| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Iopentol does not bind to a specific protein target. Its function is physical: the iodine atoms in the molecule absorb X-rays due to their high atomic number, creating radiographic contrast. When injected into blood vessels or body cavities, it opacifies these structures, making them visible under X-ray.
|
|---|---|
| ln Vitro |
In vitro, iopentol is used as an imaging agent in phantoms to calibrate X-ray and CT equipment. It has no cytotoxic or pharmacodynamic activity. It is chemically stable and non-reactive with blood components. Its iodine content (300-350 mg/mL in formulations) determines the degree of X-ray attenuation.
|
| ln Vivo |
Dedicated in vivo animal studies have demonstrated the safety and efficacy of iopentol for vascular opacification. It is rapidly distributed in the intravascular space after injection and is excreted unchanged by the kidneys via glomerular filtration. It does not undergo significant metabolism.
|
| Enzyme Assay |
In vitro assays are not performed for this contrast agent. Its physicochemical properties, such as osmolality, viscosity, and iodine content, are characterized. The opacification effect is measured using X-ray attenuation or CT number (Hounsfield units) in comparison to water and reference standards.
|
| Cell Assay |
Cell-based assays are not performed for iopentol. As an inert contrast agent, it is not intended to interact with cellular targets. Cytotoxicity studies are not required for regulatory approval beyond standard biocompatibility testing (e.g., hemolysis, pyrogenicity) according to ISO 10993 standards for medical devices.
|
| Animal Protocol |
In animal studies (typically dogs, rabbits, or pigs), iopentol is administered intravenously or intra-arterially at clinically relevant doses (e.g., 1-2 mL/kg of 300-350 mg I/mL). Contrast enhancement in blood vessels (e.g., aorta, renal arteries) is measured by CT or digital subtraction angiography. Safety is assessed by monitoring vital signs and renal function.
|
| ADME/Pharmacokinetics |
Iopentol is an extracellular contrast agent. After intravenous injection, it rapidly distributes in the intravascular space. It has a distribution half-life of approximately 20-30 minutes and an elimination half-life of 1-2 hours in patients with normal renal function. It is excreted unchanged by glomerular filtration with no significant metabolism.
|
| Toxicity/Toxicokinetics |
Iopentol has a favorable safety profile. Common adverse reactions include nausea, headache, and injection site pain. Serious adverse events such as anaphylactoid reactions, nephrotoxicity, or contrast-induced acute kidney injury are rare. Iopentol is considered to have lower osmolality and lower risk of adverse reactions compared to older ionic contrast agents.
|
| Additional Infomation |
Iopental sodium is an aminobenzoic acid. Iopental sodium is used as a contrast agent.
Iopentol is a commercially available X-ray contrast agent marketed under the brand name Imagopaque (GE Healthcare). It is approved for use in multiple countries for angiography, urography, and CT imaging. It belongs to the class of low-osmolar nonionic monomers (LOCM). It is a diagnostic drug, not a therapeutic. |
| Molecular Formula |
C20H28N3O9I3
|
|---|---|
| Molecular Weight |
835.163020000001
|
| Exact Mass |
834.896
|
| CAS # |
89797-00-2
|
| PubChem CID |
56016
|
| Appearance |
White to off-white solid powder
|
| Density |
2.095g/cm3
|
| Boiling Point |
858.8ºC at 760 mmHg
|
| Flash Point |
473.2ºC
|
| Index of Refraction |
1.693
|
| LogP |
0.176
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
35
|
| Complexity |
668
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(I)=C(N(CC(COC)O)C(C)=O)C(I)=C(C(NCC(CO)O)=O)C=1I)NCC(CO)O
|
| InChi Key |
IUNJANQVIJDFTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)
|
| Chemical Name |
5-[acetyl-(2-hydroxy-3-methoxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1974 mL | 5.9869 mL | 11.9738 mL | |
| 5 mM | 0.2395 mL | 1.1974 mL | 2.3948 mL | |
| 10 mM | 0.1197 mL | 0.5987 mL | 1.1974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
